MeiraGTx (MGTX) General Counsel Robert Wollin Buys 100,000 Shares

Robert Wollin, the General Counsel and Secretary for MeiraGTx Holdings plc, recently acquired 100,000 shares of the company. This transaction took place on June 25, 2026, and highlights insider activity within the biotech firm. The shares were acquired at no cost, as part of a transaction code marked 'A'.

Insider Buying and Selling at MeiraGTx Holdings plc

In addition to Robert Wollin, several other insiders at MeiraGTx made significant stock purchases on June 25, 2026. President and CEO Alexandria Forbes acquired 980,000 shares, while Chief Scientific Officer Stuart Naylor purchased 70,000 shares. Chief Medical Officer Robert Zeldin and CFO & COO Richard Giroux both added 100,000 and 980,000 shares respectively to their holdings. These transactions were not made under any prearranged trading plan.

Other Institutional Activity in MeiraGTx Holdings

Institutional investors have also been active in MeiraGTx Holdings. Rubric Capital Management LP increased its stake by 824,669 shares, resulting in a 13.4% boost to 7 million shares valued at approximately $60.6 million. Millennium Management LLC added 289,309 shares, a 9.1% increase, bringing its total to nearly 3.47 million shares worth about $30 million. Other major holders like Sanofi and Johnson & Johnson maintained their positions without any change.

MeiraGTx Holdings plc Stock Down 5.4%

As of Tuesday, shares of MeiraGTx Holdings plc (NasdaqGS: MGTX) were trading near $12.54. The biotechnology company has a market capitalization of approximately $1.12 billion. While the firm is not currently profitable, it has a forward P/E ratio of -8.7 and a beta of 1.257, indicating some volatility compared to the broader market. The stock's 52-week range spans from $6.31 to $12.28, with a 50-day moving average of $9.86 and a 200-day average of $8.52.

Recent Earnings

MeiraGTx Holdings reported revenue of $79.76 million, though it faced a revenue decline of 84.8%. The company is not currently profitable, with a net margin of -151.1%. MeiraGTx is expected to announce its next earnings on August 13, 2026.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on MeiraGTx Holdings. RBC Capital reiterated its buy rating on May 15, 2026, with a price target of $25. Piper Sandler and Evercore ISI Group also maintained buy ratings with targets of $30 and $18, respectively. Overall, the consensus among analysts is a strong buy, with a mean price target of $28.25 based on eight opinions.

About MeiraGTx Holdings

MeiraGTx Holdings plc is a clinical-stage genetic medicines company based in New York, NY. It focuses on developing treatments for serious diseases, particularly in the areas of ocular and neurodegenerative diseases. The company is involved in several clinical trials for gene therapies targeting conditions like Parkinson's disease and retinal dystrophies. Dr. Alexandria Forbes, Ph.D., serves as the CEO, leading a team of over 400 employees.

Bottom Line

The recent insider buying activity at MeiraGTx Holdings highlights confidence within the company's leadership. This, combined with institutional interest and a positive analyst outlook, makes the stock one to watch. However, it's important to note that 13F filings and insider transactions are backward-looking and may not reflect current positions or future performance.